IL-17REL is a member of the interleukin-17 (IL-17) family of cytokines, which are known for their role in inflammatory processes and host defense against infections. This family includes several members, such as IL-17A through IL-17F, each encoded by different genes and exhibiting distinct but related biological functions. IL-17 cytokines are predominantly produced by a unique subset of T cells known as Th17 cells, although other cell types like γδ T cells and innate immune cells can also produce them under certain conditions.
IL-17REL is the least characterized member of the IL-17 family and shares sequence homology with other IL-17 family cytokines, suggesting it may have similar biological activities. The "REL" suffix denotes its relationship to the other IL-17 family members, but also its distinctiveness, as it is not as extensively studied. Due to the naming conventions of cytokines, the "REL" might imply a relative or a homolog to the better-characterized IL-17 cytokines, particularly IL-17A and IL-17F, which are the most studied and are known to mediate pro-inflammatory responses.While the exact function of IL-17REL is not well-defined, it is presumed to be involved in immune system signaling pathways, contributing to the orchestration of immune responses. Like other IL-17 cytokines, it may play a role in inducing the production of other pro-inflammatory molecules, such as chemokines and cytokines, which recruit and activate other immune cells to the site of infection or inflammation.
関連項目
製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMAはプロテインキナーゼCを活性化し、IL-17RELの発現を高める転写因子であるNF-κBの活性化につながる。 | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $96.00 $166.00 $459.00 $1615.00 | 12 | |
LPSはTLR4に結合し、NF-κBを活性化するシグナル伝達カスケードを開始し、免疫細胞におけるIL-17RELの発現を増加させる可能性がある。 | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $100.00 $300.00 $500.00 $1528.00 | 12 | |
ResiquimodはTLR7とTLR8を活性化し、炎症性サイトカインを誘導し、IL-17RELをアップレギュレートする可能性があります。 | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
TLR7アゴニストであるイミキモドは自然免疫系を刺激し、IL-17RELの発現を誘導する可能性がある。 | ||||||
Dexamethasone Sodium Phosphate | 2392-39-4 | sc-204715 sc-204715A | 100 mg 500 mg | $54.00 $155.00 | 7 | |
これらのTLR9アゴニストはNF-κBの活性化を促進し、IL-17RELの発現を増加させる。 | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
このTLR1/2アゴニストは、NF-κBの活性化とIL-17RELの潜在的なアップレギュレーションをもたらすシグナル伝達カスケードを引き起こす可能性がある。 | ||||||
Polyinosinic-polycytidylic acid potassium salt | 31852-29-6 | sc-202767 | 5 mg | $194.00 | ||
TLR3アゴニストとしてIRF3とNF-κBを活性化し、おそらくIL-17RELの発現を促進する。 |